No, according to a multicenter randomized trial from China.
Whether to continue anticoagulation for several hours after percutaneous coronary intervention (PCI) in patients with ST-segment–elevation myocardial infarction (STEMI) remains uncertain. In a large multicenter placebo-controlled trial in China (RIGHT; NCT03664180), the authors randomized patients to prolonged (at least 48 hours) low-dose anticoagulation (with enoxaparin, intravenous unfractionated heparin, or bivalirudin) or matching placebo. The primary endpoint was a composite of all-cause death, myocardial infarction, stroke, definite stent thrombosis, and urgent revascularization at 30 days.
Overall, 2989 patients with STEMI underwent PCI with full-dose bivalirudin-based procedural anticoagulation and up to 4 hours of postprocedural inf…
Reviewing Author
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis
DisclosuresGrant/Research SupportBrigham and Women’s Hospital; American Heart Association and VIVA Physicians
Editorial BoardsThrombosis Research; Thrombosis and Haemostasis; Journal of the American College of Cardiology
Leadership Positions in Professional SocietiesSociety for Vascular Medicine (Research, Quality, and Publications Committee member); International Society on Thrombosis and Haemostasis